NASDAQ · STOCK
United Therapeutics
$536.00
52W $272.12 – $609.35
59/100
—
18.1
0.58
Explore UTHR Further
Is UTHR Bullish or Bearish?
Mixed.
Innellis AI committee rates United Therapeutics (UTHR) Watch with a composite score of 59/100
, based on 7 analysts with 57% agreement.
Last updated July 20, 2026.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Growth Analyst remains cautious — growth rate is decelerating quarter over quarter -- the trend line matters more than the level. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Weekly trend: uptrend.
- Daily downtrend but weekly uptrend — possible early reversal but not yet confirmed on the daily.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- MACD histogram is negative (-1.505) — bearish momentum.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 20, 2026
Overall Committee Score
59/100
Agreement
57%
Analysts
7
Conviction
Contested
Value Analyst
bullish
65
/ 100 · High confidence
Classic value case: cheap on multiples with earnings power to back it up
+ ROE of 19.2% shows genuine earnings power backing the valuation
Growth Analyst
bearish
38
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 12 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2975.52)
Investment Thesis Evolution
Committee score moved marginally from 59.2 to 59.2.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Portfolio Manager: +1 bearish signal(s).
Comparing 2026-07-19 to 2026-07-20 (1 day apart).
Technical Analysis
RSI (14)
38.7
Neutral
MACD Histogram
-1.504
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$458.18
Resistance
$606.61
Bollinger %B
0.16
Inside Bands
Price vs Moving Averages
EMA 9
$536.28
Below
EMA 21
$541.89
Below
EMA 50
$547.29
Below
EMA 200
$503.80
Above
Fundamental Analysis
Valuation
62
Growth
20
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
18.1×
P/B Ratio
3.90×
PEG Ratio
2.27
Dividend Yield
0.00%
52W High
$609.35
52W Low
$272.12
Quality & Growth
ROE
18.8%
ROA
16.9%
Gross Margin
86.6%
Operating Margin
45.3%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of 18.1 (inexpensive relative to a 15-40x range); Price-to-book of 3.9x; PEG ratio of 2.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.2%; Return on assets of 0.2%; Net margin of 0.4%; Gross margin of 0.9%; Current ratio of 4.79 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow margin of 0.7% (thin cash generation); Free cash flow per share is positive (23.38); Most recent quarter missed estimates by 16.9%; EPS growth decelerating (+7.5% -> -24.4% QoQ); Analyst estimates falling over recent quarters
Key Risks
- MACD histogram is negative (-1.505) — bearish momentum.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full UTHR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile